Next generation sequencing (NGS) panels and library preparation products for accurate detection of genetic variants
The application of next generation sequencing (NGS) technologies to cancer research in recent years has provided novel insights into disease initiation, progression and response to therapy. This powerful technique allows for accurate analysis of nucleotide-level aberrations such as single nucleotide variants (SNVs) and small insertions and deletions.
The SureSeq™ NGS product range includes customisable, pre-optimised NGS cancer panel content and pre-designed targeted sequencing panels for research into a wide range of cancer types and library preparation products for a streamlined NGS workflow.
SureSeq myPanel™ gene lists and exon coverage examples
Alternatively, view gene lists and exon coverage examples for the following cancer types:
- Breast Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer
- Core MPN
- MPN/MDS overlap
Can't see a panel that exactly meets your requirements, let us know the genes you are interested in and we'll create it.
SureSeq myPanel NGS Custom Cancer Panels
A regularly updated, expert-curated library of pre-optimised cancer panel content for you to select from. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact research requirements.
Web Tool: Choosing the best enrichment assay - enhanced performance of hybridisation-based NGS assays
A well-designed sequence enrichment step is vital to the success of targeted sequencing. Hybridisation offers a number of benefits over amplicon-based assays. Learn how you can enure NGS success by selecting the best enrichment assay for your needs.
Video: Create your perfect cancer research panel with SureSeq myPanel NGS Custom Cancer Panels
Discover how quick and easy it is to get started with your SureSeq myPanel NGS Custom Cancer Panel. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact requirements.
Poster: The application of a hybridisation-based next-generation sequencing (NGS) enrichment panel for the analysis of key genes involved in ovarian and breast tumours using DNA from FFPE samples
Presented at the 2017 Cancer Genomics Consortium (CGC) annual summer meeting in Denver, USA, this poster illustrates the SureSeq hybridisation-based approach as a robust method for the identification of germline and somatic mutations in TP53, BRCA1, and BRCA2 clinical research samples and how it is possible to obtain important sequence information from as little as 50 ng of formalin-compromised DNA.
SureSeq and myPanel: For research use only; not for use in diagnostic procedures.